AR025691A1 - USE OF CSAIDS IN INFECTIONS BY RINOVIRUS - Google Patents

USE OF CSAIDS IN INFECTIONS BY RINOVIRUS

Info

Publication number
AR025691A1
AR025691A1 ARP000104866A ARP000104866A AR025691A1 AR 025691 A1 AR025691 A1 AR 025691A1 AR P000104866 A ARP000104866 A AR P000104866A AR P000104866 A ARP000104866 A AR P000104866A AR 025691 A1 AR025691 A1 AR 025691A1
Authority
AR
Argentina
Prior art keywords
rinovirus
csaids
infections
symptoms
csbp
Prior art date
Application number
ARP000104866A
Other languages
Spanish (es)
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of AR025691A1 publication Critical patent/AR025691A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Otolaryngology (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente está dirigida al uso de un inhibidor de CSBP/p38 para el tratamiento de los síntomas del resfriado comun y de la exacerbacion de los síntomasasociados con el mismo en personas.This is directed to the use of a CSBP / p38 inhibitor for the treatment of symptoms of the common cold and the exacerbation of symptoms associated with it in people.

ARP000104866A 1999-09-17 2000-09-17 USE OF CSAIDS IN INFECTIONS BY RINOVIRUS AR025691A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US15449499P 1999-09-17 1999-09-17

Publications (1)

Publication Number Publication Date
AR025691A1 true AR025691A1 (en) 2002-12-11

Family

ID=22551566

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000104866A AR025691A1 (en) 1999-09-17 2000-09-17 USE OF CSAIDS IN INFECTIONS BY RINOVIRUS

Country Status (17)

Country Link
EP (1) EP1223924A4 (en)
JP (1) JP2003516314A (en)
KR (1) KR20020032591A (en)
CN (1) CN1382044A (en)
AR (1) AR025691A1 (en)
AU (1) AU7584500A (en)
BR (1) BR0014041A (en)
CA (1) CA2385722A1 (en)
CO (1) CO5200855A1 (en)
CZ (1) CZ2002939A3 (en)
HU (1) HUP0204333A3 (en)
IL (1) IL148329A0 (en)
NO (1) NO20021301L (en)
PL (1) PL363116A1 (en)
TR (1) TR200200673T2 (en)
WO (1) WO2001019322A2 (en)
ZA (1) ZA200202060B (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7301021B2 (en) 1997-07-02 2007-11-27 Smithkline Beecham Corporation Substituted imidazole compounds
WO2002060869A2 (en) * 2000-10-19 2002-08-08 Smithkline Beecham Corporation Use of p38 inhibitors for the treatment of inflammation-enhanced cough
DK1333833T3 (en) 2000-10-23 2011-12-12 Glaxosmithkline Llc New trisubstituted 8H-pyridol [2,3-d] pyrimidin-7-one compound for the treatment of CSBP / RK / p38 kinase-mediated diseases
WO2003080024A2 (en) * 2002-03-20 2003-10-02 Elan Pharma International, Ltd. Nanoparticulate compositions of map kinase inhibitors
PL372963A1 (en) * 2002-04-05 2005-08-08 Boehringer Ingelheim Pharma Gmb & Co.Kg Method of treating mucus hypersecretion
EP1707205A2 (en) * 2002-07-09 2006-10-04 Boehringer Ingelheim Pharma GmbH & Co. KG Pharmaceutical compositions of anticholinergics and p38 kinase inhibitors in the treatment of respiratory diseases
JP4593953B2 (en) * 2004-03-30 2010-12-08 杏林製薬株式会社 Rhinovirus infection prophylaxis
CA2575932A1 (en) * 2004-08-04 2006-02-16 Schering Corporation Pharmaceutical formulations comprising pleconaril for the treatment of airway diseases
MY145281A (en) 2005-03-25 2012-01-13 Glaxo Group Ltd Novel compounds
WO2009116944A1 (en) * 2008-03-20 2009-09-24 Krister Tano Use of a substance for manufacturing of a medicament for treatment of common cold
GB0905955D0 (en) 2009-04-06 2009-05-20 Respivert Ltd Novel compounds
EP2477642A4 (en) * 2009-09-17 2013-03-13 Mutual Pharmaceutical Co Method of treating asthma with antiviral agents
GB201010193D0 (en) * 2010-06-17 2010-07-21 Respivert Ltd Medicinal use
GB201010196D0 (en) * 2010-06-17 2010-07-21 Respivert Ltd Methods
US11730760B2 (en) 2011-04-01 2023-08-22 The Bioregentech Institute, Inc. Laser assisted wound healing protocol and system
US11389663B2 (en) 2011-04-01 2022-07-19 Bioregentech, Inc. Laser assisted wound healing protocol and system
GB201611712D0 (en) 2016-07-02 2016-08-17 Hvivo Services Ltd Methods and compounds for the treatment or prevention of severe or persistent influenza
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
WO2019071147A1 (en) 2017-10-05 2019-04-11 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce dux4 and downstream gene expression for the treatment of fshd
GB201721793D0 (en) * 2017-12-22 2018-02-07 Hvivo Services Ltd Methods and compunds for the treatment or prevention of hypercytokinemia and severe influenza
WO2021216754A1 (en) * 2020-04-21 2021-10-28 Spring Discovery, Inc. Use of p38 mapk inhibitors for prevention and treatment of aging and aging-related disorders and for boosting an immune system

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3927216A (en) * 1971-06-01 1975-12-16 Icn Pharmaceuticals 1,2,4-Triazol E-3-carboxamides for inhibiting virus infections
US3984396A (en) * 1971-06-01 1976-10-05 Icn Pharmaceuticals, Inc. 1-(β,-D-ribofuranosyl)-1,2,4-triazole acid esters
US5656644A (en) * 1994-07-20 1997-08-12 Smithkline Beecham Corporation Pyridyl imidazoles
IL118544A (en) * 1995-06-07 2001-08-08 Smithkline Beecham Corp Imidazole derivatives, process for their preparation and pharmaceutical compositions comprising them
AP9700912A0 (en) * 1996-01-11 1997-01-31 Smithkline Beecham Corp Novel cycloalkyl substituted imidazoles
JP2002534385A (en) * 1999-01-08 2002-10-15 スミスクライン・ビーチャム・コーポレイション New compound

Also Published As

Publication number Publication date
NO20021301D0 (en) 2002-03-15
EP1223924A2 (en) 2002-07-24
TR200200673T2 (en) 2002-12-23
CA2385722A1 (en) 2001-03-22
BR0014041A (en) 2003-07-15
AU7584500A (en) 2001-04-17
WO2001019322A3 (en) 2001-10-04
HUP0204333A3 (en) 2004-07-28
CN1382044A (en) 2002-11-27
PL363116A1 (en) 2004-11-15
EP1223924A4 (en) 2004-07-14
JP2003516314A (en) 2003-05-13
ZA200202060B (en) 2003-05-28
NO20021301L (en) 2002-05-16
WO2001019322A2 (en) 2001-03-22
HUP0204333A2 (en) 2003-05-28
CO5200855A1 (en) 2002-09-27
KR20020032591A (en) 2002-05-03
IL148329A0 (en) 2002-09-12
CZ2002939A3 (en) 2002-11-13

Similar Documents

Publication Publication Date Title
AR025691A1 (en) USE OF CSAIDS IN INFECTIONS BY RINOVIRUS
UY28258A1 (en) THERAPEUTIC TREATMENT
CR7042A (en) INDANIL ACILATED AMINAS AND ITS USE AS PHARMACOS
ECSP045081A (en) DERIVATIVES OF 1,8-NAFTIRIDINE AND ITS USE FOR THE TREATMENT OF DIABETES AND RELATED DISORDERS
AR056306A1 (en) ORTHROMBEMIC CRYSTAL FORM OF ASENAPINE MALEATE, PHARMACEUTICAL COMPOSITIONS AND ITS USE IN THE TREATMENT OF MENTAL DISORDERS
ECSP055851A (en) DERIVATIVES OF INDOLIL PIRAZINONA USEFUL FOR THE TREATMENT OF HYPERPROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS
TR200002759T2 (en) Cabergoline use in the treatment of leg numbness syndrome.
UY29170A1 (en) REPLACED ADENINS AND USES OF THE SAME
CY1112317T1 (en) RAPID CRYSTAL FORM OF A PYRIDASIN [4,5-B] INDOLIS PRODUCER
CR10166A (en) USE OF BENZO-FUSION HETEROCICLE SULFAMIDE DERIVATIVES FOR THE TREATMENT OF BIPOLAR DISORDER AND MANIA
ES2202855T3 (en) USE OF 5HT3 ANTAGONISTS TO PROMOTE INTESTINAL WASHING.
AR027945A1 (en) USE OF PRAMIPEXOL IN THE TREATMENT OF ADDICTION DISORDERS
UY27244A1 (en) USE OF ACID- (4´-TRIFLUORMETHYLPHENYL) - AMIDA (Z) -2- CYANO-3- HYDROXI-BUT-2-ENOIC FOR THE TREATMENT OF MULTIPLE SCLEROSIS
BR9807523A (en) Quinoxalins in triple combination with protease inhibitors and reverse transcriptase inhibitors as drugs for the treatment of AIDS.
UY27203A1 (en) USEFUL BENCIMIDAZOLS IN THE TREATMENT OF SEXUAL DYSFUNCTION
AR028772A1 (en) 5-AMINOALQUIL-PIRAZOL [4,3-D] PYRIMIDINS
MX9206563A (en) USE OF AMPHOTERICIN B DERIVATIVES AS PROTEASE INHIBITORS.
AR028411A1 (en) SEQUENCES OF NUCLENTIDS RELATED TO THE INCREASE OR DECREASE OF THE OVULATION ENDICE IN MAMEFEROS
UY26846A1 (en) PIRROLIDINE DERIVATIVES
ES2182987T3 (en) USE OF PIRROLIDINE DERIVATIVES FOR THE TREATMENT OF ALCOHOLISM.
ITRM20010708A1 (en) USE OF AN ALCANOIL L-CARNITINE FOR THE TREATMENT OF ERECTILE DYSFUNCTION.
AR106331A2 (en) N-BENZOIL-ESTAUROSPORINA, FORM II
FI952018A0 (en) Use of BHAP in combination with other non-nucleoside reverse transcriptase inhibitors for the treatment of HIV infection
BR0214848A (en) Glioblastoma treatment with Thymosin alfa-1
BR0314364A (en) Use of iv pde inhibitors to treat angiogenesis

Legal Events

Date Code Title Description
FA Abandonment or withdrawal